Maze Therapeutics is a biotechnology company that is focused on developing precision therapies for genetically defined diseases. The company's approach is based on the use of genetic modifiers, which are small molecules that can modulate the expression of disease-causing genes. Maze Therapeutics is leveraging its proprietary platform to identify and develop genetic modifiers for a range of diseases, including cancer, neurological disorders, and rare genetic diseases. The company was founded in 2019 and is headquartered in Menlo Park, California.